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Many risk factors associated with the develop-
ment of atherosclerosis also have been found to alter
brachial artery vasoactivity (BAVA).1-4 BAVA is a
noninvasive procedure that has been shown to be a
reliable screening method for the evaluation of
endothelial function in vivo, with impaired BAVA
being an early indicator of endothelial dysfunction
and atherosclerosis.1,5-7 We previously have studied
endothelial function in a group of patients with
peripheral vascular disease (PVD) and impaired glu-
cose tolerance (IGT). BAVA results were abnormal
in these patients during both fasting and oral glu-
cose tolerance test (OGTT).8
Insulin has been shown to have multiple effects
on the vascular system, with vascular dysfunction
being a hallmark abnormality associated with dia-
betes.2-4,9 Importantly, insulin resistance is consid-
ered to be pathophysiologically linked to the deteri-
oration of endothelial cell function.10-13 The thiazo-
lidinedione troglitazone acts as a ligand for a nuclear
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receptor, the peroxisome proliferator activator recep-
tor– g . The activation of this receptor stimulates a
number of insulin-responsive elements that enhance
the action of insulin.14,15 The subsequent improve-
ment of several metabolic parameters in patients with
type 2 diabetes mellitus (DM) or IGT who are treat-
ed with troglitazone is associated with a decreased
insulin resistance.16-19 The effects of troglitazone on
endothelial function, as reflected by BAVA evalua-
tion, are not known. This study was designed to eval-
uate the effect of troglitazone on endothelial cell
function in patients with IGT.
MATERIALS AND METHODS
Patient population. Seventeen male patients
between the ages of 50 and 75 years were selected
from the vascular surgery and endocrinology clinics
at the Washington DC Veterans Affairs Medical
Center. Patients with and without a history of PVD
were included. None of the patients had a history of
DM, and all had normal fasting blood glucose levels.
OGTT and a BAVA evaluation were performed in all
patients. Informed consent was obtained in accor-
dance with the Medical Center’s Institutional
Review Board.
Initial brachial artery vasoactivity and oral
glucose tolerance testing results. After an over-
night fast and abstention from tobacco and caffeine
for at least 10 hours, the patients were placed in a
quiet room with a controlled temperature of 22°C.
The procedure was performed with the patients in
the supine position with 30 degrees of head eleva-
tion. The left arm was used for the BAVA evaluation,
and the right arm was used for the venous access.
Blood was obtained for the measurement of serum
glucose. An Ultramark-9 duplex ultrasound scan
with high definition imaging (Advanced Technology
Laboratories, Bothel, Wash) and a 4-MHz to 7-MHz
probe was used to perform all brachial artery (BA)
diameter and peak systolic velocity evaluations to cal-
culate blood volume. A 5-cm long segment of the
BA was identified above the antecubital crease, and
the skin overlying the area was marked. Images of the
selected brachial artery segment were obtained in a
longitudinal view at an angle of 60 degrees. A blood
pressure cuff was placed around the arm at 5 cm
proximal to the selected ultrasonic window. BA flow
measurements were obtained. Complete BA occlu-
sion was performed by inflating the blood pressure
cuff to a pressure of 40 mm Hg above the patient’s
systolic blood pressure. Complete arterial occlusion
was confirmed by means of a duplex ultrasound scan.
After 5 minutes of BA occlusion, the cuff was deflat-
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ed and the BA flow was measured within the first
minute of cuff deflation. A 75-g OGTT was admin-
istered after the initial fasting BAVA evaluation. The
BAVA measurements and the serum glucose level
evaluations were repeated 30 minutes, 1 hour, and 2
hours after the glucose load administration. The
operating parameters were kept constant throughout
the procedure. IGT was defined as a serum glucose
level greater than 140 mg/dL and less than 200
mg/dL within 2 hours of the oral glucose challenge
(World Health Organization criteria).
Troglitazone therapy. After the initial OGTT,
the patients were grouped according to their glucose
tolerance status and the presence or absence of PVD.
Those patients with a normal OGTT result and no
evidence of PVD received no further evaluation and
served as an age-matched control group. The patients
with PVD and IGT were given an oral dose of 400
mg of troglitazone per day for 4 months. The patients
were instructed to maintain their usual diet and nor-
mal activity level and to continue taking all other
medications. The OGTT and BAVA assessments, as
described above, were repeated after 2 and 4 months
of troglitazone therapy. The levels of hemoglobin-
A1c, triglycerides, total cholesterol, and liver enzymes
were measured throughout the study.
Statistical analysis. All the results are reported
as the mean ± the standard error of the mean. Paired
t tests were used to determine the differences before
and after BA occlusion. The area under the curve
was used to evaluate the improvement in glucose
tolerance during the OGTT. One-way analysis of
variance with the post hoc Tukey test was used for
comparison of the groups. A P value of less than .05
was considered significant.
RESULTS
Seven patients with no evidence of PVD and with
a normal OGTT result served as the control group,
and 10 patients with IGT and a history of PVD
formed the treatment group. These patients were
treated with troglitazone for 4 months. Two patients
dropped out of the study after 2 months of troglita-
zone therapy. The 2 groups were similar with regards
to age, race, body mass index, and fasting serum glu-
cose levels (Table I). In the treatment group, 8
patients (80%) had hypertension and 8 patients
(80%) had a history of tobacco use, as compared with
3 patients (43%) with hypertension and 4 patients
(57%) who smoked in the control group. The initial
fasting BA flow before arterial occlusion was not sta-
tistically different in both groups (control, 186 ± 39
mL/min; treatment, 204 ± 31 mL/min). The treat-
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ment group had a markedly abnormal response to
hyperemia, which showed no significant increase in
the BA flow after occlusion except at 1 hour into the
OGTT (Fig 1; Table II). In comparison, the control
group had normal BAVA results, with a statistically
significant increase in the flow after BA occlusion
when fasting and during all phases of the OGTT (Fig
2; Table II).
After 2 months of troglitazone therapy, the fast-
ing BAVA results remained abnormal in the treat-
ment group, but the BAVA results during the OGTT
began to normalize. There was a significant increase
in the BA flow after BA occlusion at each step of the
OGTT (Fig 3; Table II). By the end of 4 months of
troglitazone therapy, the BAVA results normalized
both during fasting and during the OGTT, which
showed a significant increase in the flow after BA
occlusion at all 4 study points (Fig 4; Table II). These
results are comparable with the control group results
(Fig 2) because there was no significant difference
when the hyperemic response of the control group
was compared with the hyperemic response of the
study group at 4 months after troglitazone treatment
(P > .05, at each step of the OGTT).
Fig 1. Brachial artery blood flow in treatment group at baseline. Comparison of brachial
artery flow (mL/min) before and after 5 minutes of brachial artery occlusion at each step of
oral glucose tolerance test. Data are expressed as mean ± standard error of mean. Paired t test
was used to compare brachial artery flow before and after brachial artery occlusion.
Table I. Demographic information
Control Treatment 
group group




Body mass index 27.2 ± 1.9 29.0 ± 1.7
Fasting glucose level (mg/dL) 91.6 ± 3.15 99.0 ± 4.7
Hypertension 3 8
Smoking 4 8
Abnormal ABI 0 6
Claudication 0 2
Previous bypass grafting procedure 0 1
Major amputation 0 1
ABI, Ankle brachial index.
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Fig 2. Brachial artery blood flow in age-matched control group. Comparison of brachial
artery flow (mL/min) before and after 5 minutes of brachial artery occlusion at each step of
oral glucose tolerance test. Data are expressed as mean ± standard error of mean. Paired t test
was used to compare brachial artery flow before and after brachial artery occlusion.
Table II. Comparison of brachial artery blood flow before and after brachial artery occlusion at each step
of oral glucose tolerance test in the control group and the treatment group before and after troglitazone
treatment
Fasting 30 minutes 1 hour 2 hours
Age-matched control group
(n = 7) Pre 186 ± 39 180 ± 23 219 ± 33 199 ± 39
Post 498 ± 110* 381 ± 51* 490 ± 106* 359 ± 73*
Positive OGTT results before troglitazone 
treatment
(n = 10) Pre 204 ± 31 200 ± 35 180 ± 29 179 ± 37
Post 224 ± 35 270 ± 52 262 ± 39* 242 ± 56
2 months of troglitazone treatment
(n = 10) Pre 191 ± 44 158 ± 32 153 ± 29 178 ± 30
Post 231 ± 38 303 ± 45* 373 ± 58* 370 ± 68*
4 months of troglitazone treatment
(n = 8) Pre 188 ± 34 288 ± 37 220 ± 35 173 ± 21
Post 450 ± 115* 387 ± 56* 397 ± 50* 509 ± 105*
Pre, Before brachial artery occlusion; Post, after brachial artery occlusion; OGTT, oral glucose tolerance test. 
*P < .05, by paired t test.
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The metabolic effects of troglitazone revealed an
improvement in glucose tolerance, which reached a
12.3% decrease in the glucose area under the curve.
However, this decrease did not reach statistical sig-
nificance (Table III). In addition, hemoglobin A1c
and fasting glucose levels did not change with the
troglitazone treatment (Table III). No patient expe-
rienced a significant change in levels of cholesterol,
triglycerides, or liver enzymes, or reported adverse
effects from troglitazone therapy.
Fig 3. Brachial artery blood flow in treatment group at 2 months after troglitazone treatment.
Comparison of brachial artery flow (mL/min) before and after 5 minutes of brachial artery
occlusion at each step of oral glucose tolerance test. Data are expressed as mean ± standard
error of mean. Paired t test was used to compare brachial artery flow before and after brachial
artery occlusion.
Table III. Diabetes-related baseline data of the control group at enrollment and of the treatment group
before troglitazone treatment and at 2 and 4 months of troglitazone treatment
Control group Treatment group
No treatment Before 2 months 4 months
Fasting glucose level (mg/dL) 91.6 ± 3.15 99.0 ± 4.7 102.0 ± 6.1 92.8 ± 3.6
Hemoglobin A1c (%) 5.73 ± 0.12 5.73 ± 0.13 5.87 ± 0.2 5.60 ± 0.15
Glucose area under the OGTT curve 236.1 ± 14.42* 348.6 ± 17.63 305 ± 10.65 304.87 ± 12.76
OGTT, Oral glucose tolerance test.
Each value is expressed as the mean ± the standard error of the mean, with P < .05 between the control group at baseline and the treat-
ment group at each point of the study. No significant difference was found in the study group before and after troglitazone treatment.
*P < .05.
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DISCUSSION
Impaired glucose tolerance occurs in 11% of the
general population,20 but we have reported a preva-
lence rate of 39% in patients with PVD.8 It is firmly
established that diabetes is an independent risk fac-
tor for the development of atherosclerosis, with
patients with type 2 DM characteristically having
involvement of the infragenicular vessels. The roles
of insulin and glucose in the pathogenesis of athero-
sclerosis have been extensively studied. Previous
studies from our laboratory have shown that the
proliferation of infragenicular vascular smooth mus-
cle cells (VSMC) is stimulated when the cells are
exposed to increased levels of insulin and glucose in
vitro.21,22 Both IGT and type 2 DM are associated
with abnormally high serum levels of insulin as a
result of insulin receptor resistance.12,23 Endothelial
cell dysfunction occurs early in the development of
atherosclerosis, and insulin and glucose are both
known to be initiators of endothelial dysfunction.
Traditional therapy of DM with insulin may increase
the serum insulin levels even more. Potentially, this
may result in the acceleration of endothelial dys-
function and a more rapid progression of atheroscle-
rosis. The treatment of DM with agents other than
insulin may avoid this complication and provide the
benefit of a less rapid progression of atherosclerosis.
Troglitazone, an insulin sensitizer, has been shown
to increase the number of glucose transporters
(GLUT1 and GLUT4) at the cellular level.14 This
results in an improvement in many of the metabolic
abnormalities that are associated with insulin resis-
tance.15,17,19 Troglitazone may have the additional
effect of improving the endothelial-dependent blood
Fig 4. Brachial artery blood flow in treatment group at 4 months after troglitazone treatment.
Comparison of brachial artery flow (mL/min) before and after 5 minutes of brachial artery
occlusion at each step of oral glucose tolerance test. Data are expressed as mean ± standard
error of mean. Paired t test was used to compare brachial artery flow before and after brachial
artery occlusion.
flow in patients with endothelial dysfunction. There
are several known mechanisms that may be responsible
for this action. Troglitazone has been shown to
decrease peripheral vascular resistance. The stimulation
of endothelial-derived nitric oxide production and the
decrease of VSMC intracellular calcium are two poten-
tial mechanisms for this action.24-28 Troglitazone
blocks the effects of platelet-derived growth factor 
and basic fibroblast growth factor on VSMC.29
Both growth factors are known to cause vascular
smooth muscle cell contraction. Furthermore, it has
been shown that troglitazone inhibits angiotensin
II–induced proliferation and the migration of cultured
rat VSMC.30 Other studies have noted improvements
in cardiac function and a decrease in diastolic blood
pressure accompanying the hypoglycemic benefits of
troglitazone.14 In addition, troglitazone has significant
antioxidant properties and an inhibitor effect on
tumor necrosis factor a .31
In the current study, troglitazone therapy result-
ed in a marked improvement in endothelial cell
function in patients with IGT, which was shown by
an improvement in the BAVA results. This improve-
ment in the BAVA results was much greater than
that seen in glucose tolerance because glucose level
and area under the OGTT curve did not significant-
ly change (Table II). This suggests that the effect of
troglitazone on endothelial cell function and BAVA
results is through a mechanism that is not related to
its effect on insulin and glucose metabolism.
In summary, despite a modest metabolic response
to troglitazone in patients with PVD and IGT, there
was significant improvement in the BAVA results. This
effect was initially apparent as an enhanced BAVA result
during the OGTT, but, as therapy was continued, it
was apparent in the fasting state as well. The mecha-
nism underlying this improvement in endothelial func-
tion is unknown, but it appears to differ from the
mechanism of insulin-action enhancement. Further
investigation is necessary to determine the mechanisms
that are responsible for the many effects of this drug.
Because troglitazone appears to enhance endothelial
function in patients with PVD and IGT, the treatment
of patients with IGT before they become overtly dia-
betic may prove beneficial.
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Dr Linda M. Harris (Buffalo, NY). I would like to
congratulate Dr Sidawy and colleagues on a well-done
study of the effects of an oral hypoglycemic agent on the
potential role in mediating or delaying the onset of periph-
eral vascular disease. Altered compliance is known to be an
early marker for vascular disease, and endothelial cell dys-
function has been shown to precede clinically apparent
disease in hypercholesterolemia, hypertension, smoking,
aging, and diabetes. Brachial artery vasoreactivity evalua-
tion is a proven method of evaluating therapeutic inter-
ventions on endothelial cell dysfunction.
Dr Sidawy has evaluated the effects of troglitazone on
brachial artery vasoreactivity in patients with peripheral
vascular disease and in a normal control group. The study
found impaired brachial artery vasoreactivity results at
baseline and after glucose stimulation in subject patients
that normalized after 4 months of treatment. This
improvement was significantly greater than the improve-
ment seen in the glucose tolerance levels.
I have several questions for Dr Sidawy.
1. First of all, in your manuscript, you did mention
brachial artery diameter in your methods, but you
gave no results. Were there any differences? And if
not, why do you think there were no differences?
2. You mentioned that 2 patients dropped out of your
treatment group. Was this related to medication
intolerance or complications?
3. Your control group consisted of patients who had no
peripheral vascular disease and normal oral glucose
tolerance testings results. Did you consider compar-
ing, as the control group, patients who had peripher-
al vascular disease or patients without peripheral vas-
cular disease but with impaired oral glucose tolerance
testing results to see what troglitazone would do to
their brachial artery vasoreactivity?
4. In your treatment group, 80% of the patients were
smokers and 80% were hypertensive. In your con-
trol group, only 43% of the patients were hyperten-
sive and 57% were smokers. Both of these factors
are known to affect vasoreactivity. Do you think this
impacted on your outcomes?
5. Can you hypothesize on the effects of troglitazone
on patients who actually have diabetes, either
insulin-dependent or non–insulin dependent? Do
you think this may actually have an impact on delay-
ing the progression of peripheral vascular disease?
6. Lastly, what do you think the primary effect of
troglitazone was on the brachial artery vasoreactiv-
ity results? Because it does not appear to be on the
basis of the glucose and insulin metabolism, do you
think it is a result of antioxidant effect or of vascu-
lar smooth muscle cell reactions?
I would like to thank the Society for the opportunity
to discuss this paper.
Dr Anton N. Sidawy. Thank you, Dr Harris, for your
thorough discussion.
The diameter of the brachial artery is measured to
obtain the flow rate. The main endpoint that we analyzed
was the flow rate, and that was what we reported. We did
not analyze the difference in the diameter before and after
brachial artery occlusion in this study.
During this study, we encountered no complications
or untoward effects. One patient dropped out of the study
because he stopped taking troglitazone, and another
patient would not return for follow-up. We measured liver
functions for the purpose of the study, and there were no
changes during the study course.
Concerning the comparison of patients with peripher-
al vascular disease and normal oral glucose tolerance test-
ing results with those patients with peripheral vascular dis-
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ease and abnormal oral glucose tolerance test results, we
have performed this study as I mentioned during my pre-
sentation. The paper now is being evaluated for publica-
tion. We showed that there are patients with peripheral
vascular disease and normal oral glucose tolerance testing
results—those patients reacted somewhat better than the
patients with positive oral glucose tolerance testing results
to brachial artery occlusion.
As you mentioned, there was a difference in the preva-
lence of hypertension and smoking between the control
group and the study group. However, because we used
troglitazone in the study group and we compared subjects
in this group to themselves before and after troglitazone
treatment, we felt that this would cancel the effect of the
risk factors in the composition of the 2 groups.
The primary effect of troglitazone on the brachial artery
is not well elucidated yet. Troglitazone may have a direct
effect on the smooth muscle cells that cause vasodilation.
Dr Peter J. Pappas (Newark, NJ). Your data suggest
that enhanced insulin bioavailability increases vasoreactiv-
ity. Have you considered repeating this same study with
treadmill walking tests to see if it increases the walking dis-
tance? If you can extrapolate the same data from the arms
to the lower extremity, then this may have better clinical
applicability.
Dr Sidawy. I do not have a direct answer to your sug-
gestion. We have thought about the effect of troglitazone
on claudication, and it is a study worth pursuing.
Dr Jerry R. Youkey (Danville, Pa). Dr Sidawy, can
your results be explained by the effects of troglitazone on
periarterial autonomic nerve fibers instead of endothelial
cell function?
Dr Sidawy. Because brachial artery vasoactivity evalu-
ates endothelial function, the improvement of vasoactivity
by troglitazone is thought to be through an effect related
to restoring the endothelial function.
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